115.430USD+115.430盘后交易 06/24, 20:00 (美东)
关键数据
116.570今开
119.800最高
10.47M成交量
33.52市盈率 TTM
12.56市盈率动
3.320股息TTM
0.42%换手率
115.480昨收
116.570最低
719.45M成交额
17.38市盈率静
5.74市净率
2.78%股息率 TTM
7.33%ROA
125.14052周最高
0.68量比
17.12B净利润
2.49B总股本
3.5675每股收益TTM
0.22Beta
18.97%ROE
75.40052周最低
2.80%振幅
75.70%毛利率
295.39B总市值
-3.71回报/风险
1.53%风险率
操作建议
默沙东当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名37/157位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价129.52。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
默沙东简介
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
公司代码MRK
公司默沙东
CEODavis (Robert M)
网址https://www.merck.com/
常见问题
现在默沙东(MRK)的股票是买入、持有还是卖出?
根据分析师评级,默沙东(MRK)的总体评级为买入,目标价格为129.52。
默沙东(MRK)股票的每股收益(EPS TTM)是多少
默沙东(MRK)股票的每股收益(EPS TTM)是7.30。